Geographic Atrophy
Information
- Disease name
- Geographic Atrophy
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05380492 | Active, not recruiting | Phase 1/Phase 2 | Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration | November 17, 2022 | November 2025 |
| NCT05963646 | Active, not recruiting | Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study | March 16, 2021 | December 31, 2023 | |
| NCT05019521 | Active, not recruiting | Phase 2 | A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | August 23, 2021 | August 14, 2025 |
| NCT04676854 | Active, not recruiting | N/A | Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD | November 24, 2020 | February 2026 |
| NCT05536297 | Active, not recruiting | Phase 3 | Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy | September 26, 2022 | March 31, 2025 |
| NCT03846193 | Active, not recruiting | Phase 1/Phase 2 | FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD | December 17, 2018 | June 28, 2024 |
| NCT03845582 | Active, not recruiting | Phase 3 | Phase 3 Study of ALK-001 in Geographic Atrophy | May 7, 2019 | April 1, 2024 |
| NCT03894020 | Active, not recruiting | GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) | January 8, 2019 | March 2, 2024 | |
| NCT03815825 | Active, not recruiting | Phase 2 | GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) | March 4, 2019 | June 2024 |
| NCT01692938 | Completed | Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO | October 2012 | November 2012 | |
| NCT01694095 | Completed | Evolution and Risk Factors Associated With Geographic Atrophy Progression | December 2009 | August 2013 | |
| NCT01782989 | Completed | Phase 2/Phase 3 | Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA) | February 2013 | November 2020 |
| NCT01799564 | Completed | N/A | Micropulse Laser for Geographic Atrophy | August 2012 | November 27, 2013 |
| NCT01802866 | Completed | Phase 2/Phase 3 | Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride | February 2013 | May 2016 |
| NCT02130531 | Completed | Phase 1 | Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration | April 2014 | November 2015 |
| NCT00306488 | Completed | Phase 2 | OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration | March 2006 | March 2010 |
| NCT00429936 | Completed | Phase 2 | Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration | December 2006 | May 2010 |
| NCT00973011 | Completed | Phase 1 | A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy | September 2009 | July 2010 |
| NCT01002950 | Completed | Phase 2 | Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy | October 2009 | October 2012 |
| NCT01229215 | Completed | Phase 2 | A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy | February 2011 | April 2013 |
| NCT01272076 | Completed | Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE) | January 2011 | February 2011 | |
| NCT01445548 | Completed | Phase 1/Phase 2 | Sirolimus for Advanced Age-Related Macular Degeneration | September 2011 | February 2014 |
| NCT01527500 | Completed | Phase 2 | Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD) | January 25, 2012 | June 24, 2015 |
| NCT01666821 | Completed | A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population | May 2004 | January 2009 | |
| NCT02288559 | Completed | Phase 2 | A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy | March 30, 2015 | June 2, 2017 |
| NCT02332343 | Completed | Sparing of the Fovea in Geographic Atrophy Progression | October 2014 | January 2017 | |
| NCT02503332 | Completed | Phase 2 | Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy | September 24, 2015 | January 17, 2018 |
| NCT02515942 | Completed | Phase 2 | CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA) | September 25, 2015 | December 1, 2017 |
| NCT02659098 | Completed | Phase 2 | A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy | December 4, 2015 | June 5, 2019 |
| NCT02684578 | Completed | Phase 2 | Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD | April 2016 | October 2022 |
| NCT02686658 | Completed | Phase 2/Phase 3 | Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | January 20, 2016 | April 23, 2020 |
| NCT02800356 | Completed | N/A | Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD | June 2016 | September 1, 2019 |
| NCT03295877 | Completed | Phase 1 | Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) | September 21, 2017 | November 20, 2018 |
| NCT03525600 | Completed | Phase 3 | Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | August 31, 2018 | June 20, 2022 |
| NCT03525613 | Completed | Phase 3 | A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | August 31, 2018 | June 28, 2022 |
| NCT03777332 | Completed | Phase 1 | Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy | November 5, 2018 | April 1, 2021 |
| NCT04014777 | Completed | Phase 1 | Study of NGM621 in Participants With Geographic Atrophy | July 26, 2019 | May 27, 2020 |
| NCT04246866 | Completed | Phase 1 | First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration | December 19, 2019 | October 21, 2020 |
| NCT04435366 | Completed | Phase 3 | A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) | June 22, 2020 | August 22, 2023 |
| NCT04465955 | Completed | Phase 2 | A Study of NGM621 in Participants With Geographic Atrophy | July 22, 2020 | August 16, 2022 |
| NCT04615325 | Completed | Phase 1 | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration | December 8, 2020 | January 4, 2023 |
| NCT04744662 | Completed | Phase 1 | ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration | July 8, 2021 | February 29, 2024 |
| NCT05891275 | Completed | Patients With Geographic Atrophy and Their Patient Journey in the United States (US) | May 31, 2023 | December 1, 2023 | |
| NCT06006585 | Completed | Phase 1 | A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | September 12, 2023 | May 24, 2024 |
| NCT06351657 | Not yet recruiting | Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression | July 2024 | July 2027 | |
| NCT05941273 | Not yet recruiting | N/A | A Study of the SING IMT in an Israeli Cohort | July 30, 2023 | January 30, 2025 |
| NCT05961332 | Recruiting | N/A | COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy | October 6, 2023 | September 2024 |
| NCT01866371 | Recruiting | High Resolution Retinal Imaging | May 2013 | December 2027 | |
| NCT06394232 | Recruiting | Phase 1/Phase 2 | Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration. | June 4, 2024 | December 2030 |
| NCT04339764 | Recruiting | Phase 1/Phase 2 | Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration | September 23, 2020 | May 31, 2029 |
| NCT06018558 | Recruiting | Phase 1/Phase 2 | Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy | August 23, 2023 | September 23, 2025 |
| NCT06161584 | Recruiting | A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration | September 28, 2023 | October 2027 | |
| NCT06164587 | Recruiting | Phase 1 | Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy | April 18, 2024 | April 2025 |
| NCT04739319 | Recruiting | Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression | February 2, 2021 | November 2040 | |
| NCT05438732 | Recruiting | N/A | Multicenter Clinical Study of the SING-IMT in Patients With Late-stage AMD | June 16, 2022 | June 2024 |
| NCT05626114 | Recruiting | Phase 2 | A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | March 24, 2023 | April 11, 2029 |
| NCT05797896 | Recruiting | Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study | February 7, 2023 | December 31, 2026 | |
| NCT05811351 | Recruiting | Phase 2 | A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | March 6, 2023 | January 8, 2026 |
| NCT06381596 | Recruiting | N/A | Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration | April 16, 2024 | April 2025 |
| NCT05949593 | Recruiting | Phase 3 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | July 27, 2023 | November 30, 2027 |
| NCT01603043 | Terminated | Phase 2 | A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD) | June 2012 | November 2012 |
| NCT02745119 | Terminated | Phase 3 | Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) | July 21, 2016 | January 31, 2018 |
| NCT02087085 | Terminated | Phase 2 | A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration | May 9, 2014 | March 30, 2018 |
| NCT02247479 | Terminated | Phase 3 | A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | September 18, 2014 | January 29, 2018 |
| NCT02247531 | Terminated | Phase 3 | A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | October 6, 2014 | January 23, 2018 |
| NCT01602120 | Terminated | Phase 2 | An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy | May 29, 2012 | February 9, 2018 |
| NCT02479386 | Terminated | A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | June 24, 2015 | January 31, 2018 | |
| NCT01675947 | Terminated | Phase 2 | Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy | February 2012 | February 2016 |
| NCT03972709 | Terminated | Phase 2 | A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) | June 3, 2019 | October 27, 2022 |
| NCT00599846 | Terminated | The Natural History of Geographic Atrophy Progression (GAP) Study | December 2007 | ||
| NCT00890097 | Terminated | Phase 3 | Geographic Atrophy Treatment Evaluation | April 2009 | May 2012 |
| NCT04607148 | Terminated | Phase 2 | A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | November 16, 2020 | November 14, 2022 |
| NCT02137915 | Terminated | Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration | April 2014 | May 2016 | |
| NCT04643886 | Terminated | Phase 2 | A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration | July 30, 2020 | March 21, 2022 |
| NCT02399072 | Terminated | A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | March 30, 2015 | February 8, 2018 | |
| NCT05391074 | Unknown status | N/A | Oral Postbiotics in Patients With Macular Atrophy | December 1, 2020 | June 1, 2024 |
| NCT02372916 | Unknown status | Geographic Atrophy and Intravitreal Ranibizumab Injections | November 2014 | ||
| NCT04656561 | Unknown status | Phase 2 | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy | February 26, 2021 | December 31, 2023 |
| NCT02590692 | Unknown status | Phase 1/Phase 2 | Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD | February 16, 2016 | June 2023 |
| NCT02895815 | Withdrawn | Phase 2 | Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) | April 9, 2018 | August 19, 2022 |
| NCT03446144 | Withdrawn | Phase 2 | Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) | March 16, 2018 | October 10, 2018 |
| NCT04358471 | Withdrawn | Phase 2 | Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA) | July 31, 2021 | September 1, 2023 |
| NCT01093170 | Withdrawn | Phase 1 | A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy | March 2011 | September 2012 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0031609
- MeSH unique ID (MeSH (Medical Subject Headings))
- D057092